MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202517096629 A) filed by Joint Stock Company Biocad, Saint Petersburg, Russia, on Oct. 7, for 'isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof.'
Inventor(s) include Beliasnikova, Alina Valerevna; Filina, Valentina Yurevna; Ivanova, Anastasiya Andreevna; Kytmanova, Olga Leonidovna; Legotskii, Sergei Aleksandrovich; Krat, Sergei Mikhailovich; and Morozov, Dmitry Valentinovich.
The application for the patent was published on Nov. 14, under issue no. 46/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to the field of biotechnology and medicine, in particular to a bispecific antibody that specifically binds to CD3 and a tumor antigen. The invention further relates to a nucleic acid encoding the subject bispecific antibody, an expression vector, a host cell for producing the subject bispecific antibody and a method for producing said cell, pharmaceutical compositions comprising the bispecific antibody according to the invention, pharmaceutical compositions comprising the bispecific antibody according to the invention and other therapeutically active compounds, methods for treating diseases or disorders mediated by a tumor antigen, use of the bispecific antibody or pharmaceutical compositions thereof for treating diseases or disorders mediated by a tumor antigen, and the use of the bispecific antibody according to the invention and other therapeutically active compounds for treating diseases or disorders mediated by a tumor antigen."
The patent application was internationally filed on Mar. 07, 2024, under International application No.PCT/RU2024/050053.
Disclaimer: Curated by HT Syndication.
